Investigating the addition of apalutamide to androgen deprivation therapy | How clinicians decide between available treatment options.
Each day around 70 men will be diagnosed with prostate cancer in Australia. For many of these men, there can be a host of treatments available for their healthcare teams to consider.
Join us in this latest Prostate Vodcast as the esteemed Dr Axel Merseburger and Katie Clift lead a discussion on the TITAN trial — investigating the addition of apalutamide to androgen deprivation therapy for men with different types of prostate cancer — while looking to address how clinicians decide between available treatment options.
To find out more or to access support, reach out to PCFA via 1800 22 00 99
HOST
Katie Clift
Director of International Public Relations Agency may:be/ Global Moderator, Speaker & Breast Cancer Survivor
Katie Clift is Director of may:be, an international public relations agency focused primarily on nonprofits and purpose-driven organizations. An MBA scholar of Warwick Business School, Katie has worked internationally on both sides of communications – in the media (radio, television & digital journalism) and as a PR, spokesperson, and corporate affairs executive, for almost 20 years. She has a decade of experience as a moderator, presenting sessions, interviews and press conferences globally, from the World Economic Forum in Davos to the Union for International Cancer Control’s World Cancer Congress and various in-person and online events. Katie was diagnosed with aggressive breast cancer in 2022, and after 18 months of active treatment, has returned to work more determined than ever to share her story, advocate for people affected by all types of cancer, and upscale PR for purpose-driven organizations globally: those with the most important stories to tell.
PRESENTER
Dr Axel Merseburger
Professor of Urology, Chairman of the Department of Urology at the University Hospital Schleswig‑Holstein, Campus Lübeck, Lübeck, Germany
Dr Axel Merseburger is the chairman of the Department of Urology at the University Hospital Schleswig-Holstein in Lübeck, Germany. His key areas of interest are renal cell carcinoma, prostate cancer and transitional cell carcinoma, with special attention given to novel markers and prognostic factors. He is a member of the European Association of Urology (EAU) Guideline Groups on Renal Cell Cancer and has served as national and international principal investigator in several phase II/III clinical trials. Axel’s molecular and clinical research has won multiple awards, stipends and prizes, and he has authored and co-authored more that 200 publications.
